ReviewMetabolism: clinical and experimental2023
Sarcopenic obesity: emerging mechanisms and therapeutic potential.
Review in Metabolism: clinical and experimental, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 7 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Risk prediction model performances for sarcopenia in middle-aged and elderly people: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2026Pooled it
- Exercise, nutrition, physical agent therapy in older adults with sarcopenic obesity: a systematic review and network meta-analysis.BMC geriatrics · 2026Pooled it
- Effects of Concurrent Training on Biomarkers, Morphological Variables, and Physical Performance in People with Sarcopenic Obesity: A Meta-Analysis with Meta-Regression.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-A systematic mapping review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- Influence of Klotho Protein Levels in Obesity and Sarcopenia: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- BMI Association With Treatment Outcomes in Head and Neck Cancer Patients Receiving Immunotherapy: A Comprehensive Review and Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Effects of non-pharmacological interventions on body composition and physical function in older women with sarcopenic obesity: a meta-analysis.Frontiers in public health · 2025Pooled it
- Trial
- Article
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Aging-, obesity-, and diabetes-related sarcopenia: Pathogenesis and interventions.Chinese medical journal · 2026Review
- Triglyceride-related metabolic indices and low relative muscle mass: a cross-sectional analysis of SMILE and NHANES.Endocrine · 2026Article
- Cross-cohort insights into the association of handgrip strength transitions and burdens with cardiovascular disease risk.SSM - population health · 2026Article
- Delayed Loop Ileostomy Reversal Increases the Risk of Colitis and Clostridium difficile Infection.ANZ journal of surgery · 2026Article
- Aerobic Exercise Attenuates High-Fat Diet-Induced Skeletal Muscle Atrophy by Suppressing Oxidative Stress, Inflammation, and Drp1-Associated Mitochondrial Fission.Antioxidants (Basel, Switzerland) · 2026Article
- A Multidimensional Muscle Quality Index in Severe Obesity: Relationships with Ageing, Adiposity, and Functional Performance.Journal of clinical medicine · 2026Article
- Immunometabolic Plasticity in Sarcopenic Obesity: Toward a New Paradigm for Precision Immunonutrition.Nutrients · 2026Review
- Sex Differences in the Association Between Body Composition, Sarcopenic Obesity, and Periodontitis: Mediating Role of Oxidative Stress Markers.Oral health & preventive dentistry · 2026Article
- From size to function: moving beyond body mass index to frailty and central adiposity phenotypes.Intensive care medicine · 2026Article
- Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Sarcopenic obesity, or the loss of muscle mass and function associated with excess adiposity, is a largely untreatable medical condition associated with diminished quality of life and increased risk of mortality. To date, it remains somewhat paradoxical and mechanistically undefined as to why a subset of adults with obesity develop muscular decline, an anabolic stimulus generally associated with retention of lean mass. Here, we review evidence surrounding the definition, etiology, and treatment of sarcopenic obesity with an emphasis on emerging regulatory nodes with therapeutic potential. We review the available clinical evidence largely focused on diet, lifestyle, and behavioral interventions to improve quality of life in patients with sarcopenic obesity. Based upon available evidence, relieving consequences of energy burden, such as oxidative stress, myosteatosis, and/or mitochondrial dysfunction, is a promising area for therapeutic development in the treatment and management of sarcopenic obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.